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The aryl hydrocarbon receptor (AhR) is a ligand-operated tran-
scription factor originally recognized as the mediator of the toxic-
ity of dioxins. AhR is presumed to have evolved from invertebrates,
where it served a ligand-independent role in normal development
processes. Evolution of the receptor in vertebrates resulted in the
ability to bind structurally different ligands, including xenobiotics,
such as dioxin, and catabolites derived from the host’s own metab-
olism, or from the microbiota. It is now clear that AhR contributes
to immune homeostasis by promoting immunomodulatory and
host-protective effects (1, 2). It is likewise clear that the nature of
the ligand as well as the tissue specificity [e.g., gut (3), skin (4), and
lymphoid tissue] in which AhR engagement occurs largely dictate
the outcome of AhR activation.
Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the initial
rate-limiting step in degrading tryptophan along the kynurenine
pathway (5–7). Initially confined to regulation of tryptophan avail-
ability in local tissue microenvironments, IDO1 is now considered
to play a wider role that extends to homeostasis and plasticity of the
immune system. Its effects involve not only tryptophan depriva-
tion but also the production of immunoactive kynurenines, which
may act as AhR ligands (8–12). Although two additional enzymes,
i.e., IDO2 and tryptophan 2,3-dioxigenase (TDO2), catalyze the
same reaction along the kynurenine pathway (13), IDO1 is appar-
ently unique in promoting immunoregulatory effects over the long
term, owing to its ability to function as a signaling molecule
(14–16). IDO1 first appeared in placental animals by duplica-
tion of the IDO2 gene (17), suggesting that the coexistence of
two allogeneic individuals (i.e., mother and fetus) in the same
organism would require advanced strategies of immune regula-
tion capable of maintaining T-cell tolerance for prolonged periods
of time.
The appearance of higher vertebrates, and specifically mam-
mals, was, in fact, marked by the emergence of regulatory T (Treg)
cells (18, 19). Thus, an entirely new paradigm in immunology, and
more specifically in immune tolerance, may be the coevolution of
three systems, namely, the IDO1 mechanism, kynurenine-driven
gene transcription, and T-cell regulatory activity, which, originat-
ing from the initial need of protecting the fetus in mammals, have
later turned into a pivotal mechanism of peripheral tolerance in
autoimmunity, transplantation, and neoplasia.
The present Research Topic brings together 11 articles cov-
ering evolutionary aspects of tryptophan catabolic enzymes and
AhR, their role in physiology and pathogenesis. In their Review
Article, Ball et al. pointed out two interesting features emerg-
ing from studies of the dynamic evolution of TDO2, IDO1, and
IDO2 (20). The three enzymes, which belong in two distinct super-
families (TDO and IDO), have converged into the same catalytic
activity, thus underlining the critical importance of tryptophan
metabolism in all organisms. Yet, the IDO superfamily underwent
divergent evolution, which occurred by gene duplication and led
to the expression of an eclectic protein, IDO1, in placental animals.
Because Ido1−/− mice are mosaic deficient for the IDO2 function
possibly owing to an altered mRNA splicing, distinct IDO genes
may also influence the expression of each other by a still unclarified
mechanism, as suggested by Prendergast et al. (21).
Zelante et al. dealt with the adaptive properties of IDO1 and
AhR from a different perspective, i.e., taking into consideration
the possibility that tryptophan metabolism by human microbiome
has been playing a major role in shaping the coevolution of the
AhR/IDO1 axis in immune regulation (22). Interestingly, they
recently discovered a tryptophan catabolite selectively produced
by certain Lactobacilli of the human microbiome (i.e., indole-3-
aldehyde) capable of activating AhR and thus inducing the expres-
sion of IDO1 and anti-inflammatory responses (3). Tryptophan
catabolic enzymes may, however, represent a double-edged sword
in the interaction between mammals and pathogenic microbes, as
outlined by Schulze et al. (23), because tryptophan depletion exerts
bactericidal activity in tryptophan auxotrophs. Microorganisms
such as E. coli and HIV are known to highjack the immunosup-
pressive effects of IDO1, though. Intriguingly, Kishimoto et al.
discussed the possibility that microRNAs (miRNAs) may regulate
the transcriptional expression of IDO-encoding genes, mainly in
autoimmunity (24). Because miRNAs have been suggested to be
instrumental in the evolution of organismal complexity (25) and
AhR has been shown to induce the expression of several miRNAs
(26), these observations further underline the critical interde-
pendence of AhR and IDO enzymes in coping with mammalian
challenges.
In their Perspective, Orabona et al. proposed an additional level
of cross-regulation between the two systems (27), which may occur
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via AhR non-genomic effects that imply recruitment of a ubiquitin
ligase complex and consequent proteasomal degradation of target
proteins, a mechanism also considered by Quintana et al. (28).
Because IDO1 is known to be subjected to regulatory proteolysis,
AhR may not only induce but also switch off the IDO1 mechanism.
Thus, depending on the specific pathologic conditions and timing
of events, AhR may represent a friend or foe, and pollutants may
play a major role in this regard, as suggested by the Perspective
Article by Mezrich et al. (29).
Neoplasia represents a condition where drug targeting of the
AhR/tryptophan metabolism axis has made the greatest progress.
Already considered as a mechanism of immune escape in tumor
progression, the data by Hanks et al. indicate that IDO1, modu-
lated by several factors, is also involved in creating the permissive
conditions for early carcinogenetic events (30). Most of these
AhR/IDO1 modulating factors were examined by Platten et al.
as potentially indirect, yet innovative, drug targets (31). Van den
Eynde et al., thanks to the use of a highly specific anti-human IDO1
antibody, elegantly revisited the expression of this immunoregu-
latory enzyme in almost one thousand tumor specimens, finding
that IDO1 is not upregulated in tumor-draining lymph nodes as
previously reported, but it is restricted to tumor cells, stroma, and
endothelium (32).
The reviews presented in this e-book of Frontiers are meant to
provide readers with an overview of the intricacies of AhR func-
tioning in both physiology and pathology, and of the combined
effects of AhR ligand – intrinsic and – extrinsic factors, including
the local tissue, which may provide a specific set of coactivators
and functions bridging the basic transcriptional machinery to the
target genes.
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